With zero observations
Biocon announced the successful conclusion of pre-approval inspection (PAI) conducted by USFDA at oral solid dosage manufacturing facility of Biocon Pharma, a subsidiary of the company. The inspection was triggered by the submission of an abbreviated new drug application.The inspection of the Bengaluru facility, which took place between 13 - 17 January 2020 concluded with zero observations and no Form 483 was issued.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
